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ABSTRACT
Elite athletes suffer many mental health symptoms and 
disorders at rates equivalent to or exceeding those of 
the general population. COVID-19 has created new 
strains on elite athletes, thus potentially increasing 
their vulnerability to mental health symptoms. This 
manuscript serves as a narrative review of the impact 
of the pandemic on management of those symptoms 
in elite athletes and ensuing recommendations to 
guide that management. It specifically addresses 
psychotherapy, pharmacotherapy and higher levels 
of care. Within the realm of psychotherapy, crisis 
counselling might be indicated. Individual, couple/
family and group psychotherapy modalities all may be 
helpful during the pandemic, with novel content and 
means of delivery. Regarding pharmacotherapy for 
mental health symptoms and disorders, some important 
aspects of management have changed during the 
pandemic, particularly for certain classes of medication 
including stimulants, medications for bipolar and 
psychotic disorders, antidepressants and medications for 
substance use disorders. Providers must consider when 
in- person management (eg, for physical examination, 
laboratory testing) or higher levels of care (eg, for crisis 
stabilisation) is necessary, despite potential risk of viral 
exposure during the pandemic. Management ultimately 
should continue to follow general principles of quality 
health care with some flexibility. Finally, the current 
pandemic provides an important opportunity for research 
on new methods of providing mental health care for 
athletes, and consideration for whether these new 
methods should extend beyond the pandemic.
INTRODUCTION
Elite athletes (defined as professional, Olympic/
Paralympic or collegiate) suffer from many mental 
health symptoms and disorders at rates equiva-
lent to or exceeding those of non- athletes.1 The 
COVID-19 pandemic has created new mental health 
stressors for everyone; for athletes, these have been 
addressed in recent publications.2–5 However, the 
pandemic’s impact on management of mental health 
symptoms and disorders in athletes has received 
little scholarly attention. Management in general 
for athletes has focused on the cardiac complica-
tions, screening for asymptomatic disease, and 
return to sport, incorporating hygiene measures.6–8 
Here, we delineate management considerations 
for mental health symptoms and disorders in elite 
athletes. Options for management in elite athletes 
during the pandemic span various treatment modal-
ities, inclusive of community- based or outpatient 
psychotherapy, outpatient pharmacotherapy and 
higher levels of care,9 all of which are addressed 
in this article. It is likely that these considerations 
will hold relevance into the foreseeable future given 
anticipated future waves of COVID-19.
METHODS
We searched key databases (PubMed, SportDiscus, 
PsycINFO, Scopus and Cochrane) in May 2020. 
Search terms relating to COVID-19, elite athletes, 
athletes, sports, mental health, management and 
treatment were combined. No limits were placed 
on the search. Databases required slightly modified 
terminology to adhere to the databases’ controlled 
vocabulary. Papers must have been available in 
English to be included in this manuscript. Using this 
strategy, 39 articles were identified. After screening 
for relevance, this was reduced to 6. References in 
the resulting papers were reviewed to identify addi-
tional related publications. Other literature was also 
reviewed, including that focused on non- pandemic 
management recommendations for elite athletes 
and pandemic recommendations for non- athletes, 
where there were gaps in elite athlete- specific and 
COVID-19- specific literature. Altogether, 109 rele-
vant references and sources were found.
PSYCHOTHERAPY
Psychotherapy is defined as the treatment of mental 
health symptoms or disorders or problems of living 
by psychological means, often based on therapeutic 
principles, structure and techniques.10 It is often 
regarded as the treatment of choice for elite athletes 
with mild to moderate mental health symptoms and 
disorders.1 10 This would seemingly remain the case 
during the COVID-19 pandemic, with athletes 
traditionally particularly well- suited to cognitive- 
behavioural therapy because they are accustomed to 
structure, direction, practice, goal setting and self- 
reliance.10 11 However, the nature and delivery of 
psychotherapeutic interventions might vary because 
of the pandemic. For example, crisis counselling 
might be the preferred intervention12 13 for athletes 
whose mental health is primarily being affected 
by direct effects of the pandemic, such as the 
morbidity or mortality of loved ones, friends and 
members of the athlete entourage; personal illness; 
devastating loss of one’s home or job; a lost oppor-
tunity for an important athletic event (eg, World 
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Championships, Olympics) or collapse of social structure. The 
central objectives of crisis counselling, as opposed to more tradi-
tional psychotherapy, are ensuring safety, promoting return to 
functioning and providing immediately available resources.12 14 
Symptoms directly related to the pandemic might resemble those 
of acute stress disorder (for symptoms lasting 3 days to 1 month 
in duration) or post- traumatic stress disorder (PTSD, for symp-
toms lasting >1 month in duration). When these types of symp-
toms are present, PTSD- specific psychotherapy might be helpful 
for athletes (table 1).
Psychotherapy with athletes may occur at the individual, 
couple/family or group levels.10 Couple/family psychotherapy 
might be needed by some elite athletes at this time; compared 
with athletes’ usual frequent absences for travel, spending more 
time together could be a source of tensions. Group psycho-
therapy to replicate some team dynamics within therapy groups 
might also be useful for athletes during the pandemic, since 
they have lost much of their accustomed team structure.10 
These modalities are currently being offered in virtual formats 
(eg, telephone, video), depending on location.15 Despite some 
delays in converting to virtual formats, increasingly, providers of 
psychotherapy offer virtual options for patients. Online artificial 
intelligence and self- help interventions and groups, such as Alco-
holics Anonymous, are now being offered virtually as well.15 16 
However, providers and institutions with fewer resources, or 
those serving patients with fewer resources, have had more diffi-
culties in offering virtual psychotherapeutic options.17
Depending on the particular mental health disorder, virtual 
psychotherapy may involve elements not normally available 
to the psychotherapist. For example, with screen sharing, the 
psychotherapist can help an athlete with an eating disorder fill 
a grocery cart through an online delivery service or engage in a 
video session during a meal, or help an athlete with obsessive- 
compulsive disorder or sport- related performance anxiety 
engage in live exposure therapy.18 These practice changes may 
be worthy of retention post- pandemic.
As during non- pandemic times, there are many barriers to 
elite athletes commencing psychotherapy, including denial of 
psychological problems and stigma of receiving services.10 19 It 
might be more challenging than usual to overcome these barriers 
during the pandemic, when athletes have become more accus-
tomed to social withdrawal or have less contact with members 
of their entourage, who might otherwise be the first to notice 
mental health symptoms and to recommend referral for treat-
ment. Accordingly, interventions at the level of entire teams, 
leagues and university athletics departments are warranted to 
increase the likelihood of athletes being connected with the 
psychotherapeutic resources from which they could benefit. 
Non- pandemic evidence suggests that athletes and core members 
of their entourage benefit from psychoeducation, defined as an 
intervention designed to obtain and maintain mental health by 
providing information, educational materials and/or feedback/
advice to individuals who might have mental health symptoms or 
disorders.10 Thus, virtual psychoeducational sessions or written 
materials might benefit groups of athletes via provision of infor-
mation about pandemic stressors relevant to athletes, strategies 
for overcoming them and mechanisms for referral to psycho-
therapy. For those athletes referred for individual psychotherapy 
as a result of group psychoeducational interventions such as this, 
expanded psychoeducation in addition to more formal crisis 
counselling, cognitive- behavioural therapy or other psychother-
apeutic modalities if appropriate may have benefit.
PHARMACOTHERAPY
Medications to treat mental health symptoms and disorders 
remain an important tool for management, especially for those 
with moderate to severe symptoms.1 For some elite athletes and 
many categories of medications, these treatments will remain the 
same. However, some circumstances have changed because of 
the pandemic; these will be highlighted here.
Stimulants
Changes to paradigms of pharmacotherapeutic management of 
elite athletes who are prescribed stimulants, for example, for 
attention- deficit/hyperactivity disorder (ADHD), are particu-
larly evident in some countries. Some jurisdictions have relaxed 
the arrangements for prescribing stimulants so that these can 
be prescribed without a face- to- face consultation subject to 
clear safeguards. Early in the pandemic, for example, the USA 
suspended the Ryan Haight Act20 that historically prohibited 
prescribing stimulants for new patients establishing care with a 
prescriber during a telehealth visit. Prescribers in the USA can 
now prescribe a stimulant if the following criteria are met: 1) the 
prescription is issued for a legitimate medical purpose by a prac-
titioner acting in the usual course of their professional practice; 
2) the telemedicine communication is conducted using an audio- 
visual, real- time, two- way interactive communication system 
and 3) the practitioner is acting in accordance with applicable 
Federal and State laws.20 This exception remains in effect for the 
duration of the public health emergency, as declared by the US 
Secretary of the Department of Health and Human Services.20
However, there are important considerations for prescribers 
who work with elite athletes. Typically, it is recommended to 
check vital signs (eg, pulse, blood pressure) and possibly labo-
ratory tests (eg, drug toxicology screen) before prescribing 
stimulants in this population.21 While no definitive guidelines 
for elite athletes are available during this pandemic, if checking 
Table 1 PTSD- type symptoms triggered by the pandemic and potential treatment modalities106–109
Symptom category Manifestations Potential modalities
Intrusion Intrusive memories, nightmares, flashbacks, intense distress or physiological 
reactivity after exposure to reminders of the trauma
 ► Trauma- focused cognitive- behavioural therapy
 ► Prolonged exposure therapy
 ► Cognitive processing therapy
 ► Eye movement desensitisation and reprocessing
Negative moods/cognitions Inability to recall events related to the trauma, distorted beliefs about the 
world, distorted blame of self/others for causing the trauma, fear, horror, guilt, 
anger, decreased interest in activities, feeling alienated from others, constricted 
affect
Altered arousal/reactivity Irritability, aggression, self- destructive behaviour, hypervigilance, exaggerated 
startle response, problems concentrating, sleep disturbance
Avoidance Shunning pandemic- related memories or external reminders of the trauma
Dissociative Numbing, detachment, decreased awareness, derealisation, depersonalisation
PTSD, post- traumatic stress disorder.
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laboratory tests remains possible, or if recent (eg, within the past 
3 months, depending on index of suspicion) results are available 
to the prescriber and no significant cardiovascular or substance 
use risk factors are present, it might be reasonable to start a stim-
ulant for an athlete never seen in- person previously. More infor-
mation on the issue of when to request an elite athlete be present 
for in- person evaluation is provided in the section “virtual versus 
in- person care” below.
Medications for bipolar and psychotic disorders
Medications most commonly used for bipolar and psychotic 
disorders are another important area of pharmacological consid-
eration for athletes during the pandemic. Typically, laboratory 
evaluations are conducted at regular intervals for patients taking 
certain mood- stabilising medications (eg, lithium, valproic 
acid)22 and atypical antipsychotics (eg, aripiprazole, quetiapine, 
clozapine).23 For lithium, routine laboratory tests include lithium 
blood levels, thyroid function and kidney function.22 Lithium 
can be a particularly challenging medication to prescribe in 
athletes because blood levels may fluctuate during high- intensity 
exercise, sweating and associated dehydration—or as a conse-
quence of sport- associated eating disorders.1 24–27 Thus, while 
some prescribers might be willing to delay routine laboratory 
monitoring for non- athletes during the pandemic,28 such a delay 
might well be inadvisable for athletes. This might especially be 
true in locations where the pandemic is overlapping with warmer 
seasons, during which sweating and dehydration might be more 
likely in athletes. Haematological parameters of valproic acid 
and other mood stabilisers are seemingly less directly impacted 
by sport; thus, brief delays in monitoring athletes taking these 
medications might be reasonable.28 However, for any mood 
stabilisers that normally require laboratory monitoring, baseline 
values should be obtained as usual if the provider is considering 
a new prescription.22
For atypical antipsychotics, routine laboratory monitoring, 
ranging anywhere from weekly (eg, during the first months of 
starting a patient on clozapine) to annually (eg, patients stable 
on other atypical antipsychotics), is typically recommended. The 
question also arises with these agents as to how often prescribers 
should be checking laboratory tests, including fasting blood 
sugar and fasting lipids (and for clozapine, absolute neutro-
phil counts and clozapine blood levels), during the pandemic. 
Although pandemic guidelines are not readily available, nuanced 
consideration is reasonable.28 For example, if an athlete’s fasting 
blood sugar and lipids have been normal for several years, and 
they are taking a low dose of an atypical antipsychotic among 
the least likely in the class to cause metabolic disturbance (eg, 
ziprasidone, aripiprazole), it may be reasonable to delay usual 
monitoring. However, if the athlete is taking a high dose of a 
typically more metabolically problematic medication in this 
class (eg, olanzapine, quetiapine), and/or if they have had past 
abnormal or marginal fasting blood sugar or lipid values, adher-
ence to usual testing schedules seems prudent.
In some countries, including the USA, routine laboratory 
monitoring of absolute neutrophil count (ANC) is required 
for athletes taking clozapine and must be on file at the phar-
macy before they can refill the medication.29 However, during 
the pandemic, the US Food and Drug Administration has stated 
that laboratory monitoring requirements will not be enforced.30 
Thus, prescribers are advised to decide if they recommend that 
their patients get their laboratory tests done, based on current 
public health circumstances and the individual patient.30 
Recently, a consensus statement has been published stating that, 
if certain criteria are met, monitoring ANC values may occur 
every 3 months.31 However, it may be advisable to retain usual 
laboratory protocols for athletes on clozapine, especially those 
in endurance sports or with relative energy deficiency in sport 
(RED- S), as these groups may have altered immune function32 or 
lower total white cell and ANC values at baseline.33 Importantly, 
the statement also notes that patients with COVID-19 might be 
at risk of clozapine toxicity.31
For all antipsychotic medications, providers would normally 
conduct baseline and intermittent Abnormal Involuntary Move-
ment Scale (AIMS) examinations to evaluate for movement 
disorders such as tardive dyskinesia that can result from these 
medications. A partial AIMS examination can be conducted 
via virtual video appointment, but full implementation would 
require in- person visits at periodic intervals34 and would 
be recommended for elite athletes, whose careers would be 
impacted by movement disorder side effects of medications.24
Antidepressants
For many antidepressants, there does not appear to be any new 
or unique guidance to offer for athletes during the pandemic. 
Tricyclic (eg, amitriptyline, nortriptyline) and serotonin- 
norepinephrine reuptake inhibitors (eg, venlafaxine, duloxetine) 
may be exceptions, although there are no published pandemic 
guidelines for these medications. As with lithium, blood levels of 
tricyclic antidepressants might fluctuate depending on exercise 
status, although this has not been well- studied in athletes and is 
not felt to be a common problem.1 While tricyclic antidepres-
sants are not often recommended for elite athletes owing to side 
effects and safety concerns,1 if pre- pandemic blood levels were 
in the non- toxic range with no intervening changes in potentially 
interacting medications or worsening side effects,35 delayed 
checking of blood levels during the pandemic may be reasonable.
Cardiac monitoring during non- pandemic times is recom-
mended for patients taking tricyclic or serotonin- norepinephrine 
reuptake inhibitor antidepressants36 and some selective sero-
tonin reuptake inhibitors (ie, citalopram and escitalopram if high 
doses are used).37 For all of these situations, if a new prescription 
is being considered, it is reasonable to obtain a baseline and at 
least one follow- up blood pressure measurement, and an ECG 
for athletes at relatively higher risk for cardiovascular events.36 
This guidance is especially relevant for athletes, for whom 
cardiac emergencies are possible due to extreme physical activity. 
In addition, cardiac complications have been reported in 21% 
of patients hospitalised for COVID-19, leading to recommenda-
tions for advanced cardiac testing (eg, high- sensitivity troponin, 
ECG, echocardiogram) in competitive athletes who test positive 
via screening tests for COVID-19, whether they are symptom-
atic or asymptomatic.6 Moreover, athletes might be less likely 
to tolerate orthostatic hypotension as a side effect of tricyclic 
antidepressants, since they have lower average blood pressures 
at baseline.1 Thus, in sum, there are several reasons why cardiac 
monitoring of athletes on tricyclic, serotonin- norepinephrine 
reuptake inhibitor or high- doses of some selective serotonin 
reuptake inhibitors should continue unabated during the 
pandemic.
Medications for substance use disorders
During the pandemic, athletes with substance misuse and 
substance use disorders may be at increased risk of substance 
withdrawal (eg, during quarantine or isolation)38 or, conversely, 
increased use of substances,39 including recreational and ergo-
genic substances. Factors likely contributing to increased 
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substance use among athletes during the pandemic include less 
sport- related drug testing,40 social isolation, less immediate need 
to maintain fitness and meet workout goals, loss of structure and 
self- treatment of high stress levels and worsened mental health 
symptoms.38 41
During this time of potentially greater substance use risks, 
athletes may have more difficulty obtaining treatment, including 
medications, for the management of acute and post- acute 
substance withdrawal and relapse prevention.42 There have also 
been changes in allowable prescription practices and prescribing 
recommendations for substance use disorders during the 
pandemic. This is especially true for medications used to treat 
opioid use disorder and for substances more commonly misused 
by athletes, including alcohol, nicotine and cannabis.
For opioid use disorders, an increased number of take- home 
doses of methadone and buprenorphine (up to 1 month at a time) 
is now allowed in some countries.43 Elite athletes with opioid use 
disorders might be more inclined to address these issues now, if 
they are on an enforced hiatus. Opioids (including methadone 
and buprenorphine) are prohibited by the National Collegiate 
Athletic Association (NCAA),44 some professional sports leagues 
and in- competition by WADA.45 Thus, while treatment with 
these medications would typically require a break in competition 
for elite athletes,46 47 their use during the pandemic may be less 
disruptive to training/competition cycles. Urine drug testing by 
providers is typically routine in those being treated with meth-
adone and buprenorphine for opioid use disorders, but while 
accessing such testing remains difficult or risky, some groups 
have recommended that access to these medications should not 
be conditional on urine drug testing.48 With any relaxation of the 
treatment parameters for management of opioid use disorders, 
providers should be vigilant about the risk of opioid overdoses 
in their athlete- patients and consider prescription of naloxone 
for at- risk athletes and their entourage to have available in the 
event of overdose.
The pandemic has also had important implications for phar-
macologic management of alcohol misuse and alcohol use 
disorder in athletes. Athletes felt to be at risk for alcohol with-
drawal should be contacted by their providers, with details of 
how alcohol withdrawal presents, the need for medical atten-
tion if it were to develop and options for how to obtain medical 
attention. Medications to manage withdrawal, reduce cravings 
and prevent relapse on alcohol may be less available as some 
providers may not be comfortable prescribing these in an outpa-
tient setting or via telemedicine.49 However, for management 
of alcohol withdrawal, outpatient/telemedicine prescribing is 
feasible since most elite athletes have good general health and 
therefore are less likely to experience severe withdrawal (eg, 
seizures, delirium tremens) or serious medical complications (eg, 
alcohol- related hepatitis). Withdrawal can be managed using 
standard fixed- schedule or symptom- triggered protocols with 
benzodiazepines such as diazepam, lorazepam or chlorodiaz-
epoxide.50 Once acute withdrawal is managed, medications to 
reduce cravings and prevent relapse should be considered. Stan-
dard options include disulfiram, naltrexone and acamprosate, 
which have approval for these indications in some countries, and 
gabapentin, which can be used off- label.51 52 Since both disul-
firam and naltrexone can cause hepatotoxicity, liver function 
testing should be obtained before initiation and as part of moni-
toring,53 although this is more challenging during the pandemic.
Medications to manage nicotine withdrawal or to prevent 
nicotine use disorder relapse are important because oral tobacco 
use is more common in elite athletes in some sports compared 
with non- athletes,46 54 and treatment of these disorders should 
not be delayed during the pandemic given significant impact 
on health.55 While some types of nicotine replacement therapy 
(NRT) (eg, nicotine gum, lozenge and patch) are available 
without a prescription in some countries, others (eg, nicotine 
nasal spray and inhaler) may require a prescription. Other medi-
cations to consider are bupropion and varenicline, the former 
either alone or in combination with NRT.
Cannabis has become the most widely used illicit/banned 
substance by athletes in recent years.46 56 Use rates of canna-
binoids may be increasing further in some elite sports during 
the pandemic, following recent removal of cannabidiol (CBD) 
from the WADA Prohibited List in- competition57 and tetrahy-
drocannabinol (THC) and CBD from the prohibited lists in some 
professional sports,58 with reduced testing and a shift away from 
sanctions in favour of treatment in the professional sports.58 
In addition, as cannabis medicalisation and legalisation have 
expanded in several countries, levels of THC—the main psycho-
active substance in cannabis—have increased dramatically, while 
levels of CBD—a THC effect modulator—have decreased.59 The 
expanded use of high potency cannabis during the COVID-19 
pandemic may result in increased rates of cannabis use disorder 
and attendant increases in cannabis- induced cognitive impair-
ment, lack of motivation, anxiety, depression and psychosis60 in 
elite athletes.
Thus, as with other substances, treatment of cannabis use 
disorder in elite athletes should not be delayed during the 
pandemic given the potential for serious consequences. While 
the evidence base for medications to manage cannabis with-
drawal or prevent cannabis use disorder relapse is not as strong 
as for alcohol or nicotine, there are options. For withdrawal- 
related sleep and appetite disturbances, short courses of sedating 
medications such as mirtazapine or zolpidem can be considered, 
while gabapentin may help with withdrawal symptoms such as 
cravings, anxiety and memory impairment.61 While sedating 
medications may cause impaired sport performance and thus 
are not commonly recommended for long- term use in most elite 
athletes,1 short courses, especially during hiatus from sport, are 
reasonable.
General pharmacological considerations
Prior to considering changes from routine monitoring or 
prescribing protocols for psychiatric medications, risks versus 
benefits should be discussed thoroughly with the athlete. Factors 
to consider include any past laboratory or physical examination 
findings, their personal and sport- specific risks for complications 
from medications, and challenges to in- person evaluations.
Another overarching consideration in pharmacotherapy 
for athletes with mental health symptoms and disorders is 
dispensing larger quantities of medication than usual. Prescribers 
are commonly asked to approve a 90- day (or longer) supply 
of medications, often because larger supplies are cheaper for 
patients. Suicide risk and potential lethality of a given medication 
should continue to be carefully considered in such requests.62 
However, in pandemic conditions, prescribers might reasonably 
consider prescribing larger quantities of medications. In some 
geographic areas and under some coverage plans, such prescrip-
tions (with some exceptions for controlled substances) are now 
being allowed.63 64 This consideration requires the prescriber to 
balance the patient’s risks of going to a pharmacy during the 
pandemic (or running out of medication if quarantined at home), 
versus access to larger quantities of medication that could be 
dangerous if an overdose occurs. Additionally, because some 
athletes will be away for months (eg, when a future semester 
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of in- person classes/sport has been cancelled), prescribers might 
receive requests to authorise refills of up to 6 months or more of 
a medication. The same risk- versus- benefit consideration would 
apply in this situation. Finally, athletes might not be able to fill 
their prescriptions routinely in their current location, which also 
bears consideration.
VIRTUAL VERSUS IN-PERSON CARE
For some athletes, care for mental health symptoms and disor-
ders during this pandemic is being provided by telemental 
health.17 Telemental health refers to the use of information and 
communications technologies, including videoconferencing, to 
deliver mental healthcare remotely, including psychotherapy, 
mental health evaluations and medication management.65 
During the COVID-19 pandemic, virtual care protects athletes 
and healthcare providers from virus exposure and avoids care 
disruptions.17 66 During non- pandemic times, telehealth methods 
have been successfully implemented with various populations, 
across a range of mental health symptoms and disorders.67 Tele-
health for mental healthcare has not been systematically studied 
in athletes, but this method of care delivery is feasible for athletes 
with other medical needs.68–70
For athletes in some countries, remote provision of mental 
healthcare has necessitated changes in licensure rules.17 For 
example, in the USA, during non- pandemic times, a physician 
must be licensed in the state where the patient is physically 
located,17 and most physicians are only licensed in a single state.71 
Currently, many collegiate and other elite athletes may not be 
where their team, coach, university and/or healthcare providers 
are located. Several, but not all, states have loosened their licen-
sure requirements to allow telehealth care across state lines.72 In 
some cases, these new requirements are stricter for physicians 
than psychologists.72 It is difficult to determine whether interna-
tional treatment is allowed during the pandemic, and this matter 
needs further clarification. Healthcare providers should remain 
updated about any evolving licensure requirements where they 
live. This might involve checking online databases of up- to- date 
regulations in advance of each athlete’s telehealth session and 
documenting accordingly.
As in the general public, some athletes will not have access to 
relevant technology, reliable internet service or a private space, 
and they may lack the digital literacy needed to participate in a 
virtual appointment.73 Telehealth has also presented challenges 
for athletes with language barriers (eg, when the athlete speaks a 
different language than the provider) or communication- related 
disabilities (eg, when the athlete is deaf or hard of hearing).68 
Thus, while increased options for telehealth are lauded by many 
as increasing access to care, there likely are athletes for whom the 
opposite is true.73 In such cases, the provider can suggest alter-
natives, such as carefully timed, brief phone check- ins, virtual 
appointments from internet ‘hot spots’ in an athlete’s commu-
nity, use of virtual interpreters or referral to local providers 
where the athlete is now located.68
Another issue in remote mental healthcare is that of insurance/
payer coverage for services.17 66 Public and private insurers/payers 
have been covering more telehealth services recently because of 
COVID-19, but the duration of this expanded coverage is uncer-
tain.17 66 74
Finally, consideration must be given to if/when in- person 
appointments might be recommended.66 For example, remote 
care may be inadequate in cases of acute suicidality or new- 
onset psychosis. This is also a relevant concern for individuals 
with eating disorders, which are disproportionately common 
among elite athletes.75–79 It is hypothesised that COVID-19, 
with attendant food insecurity and panic buying, will exacer-
bate the already complex, problematic relationship that patients, 
including athletes, with eating disorders have with food.80 For 
athletes with eating disorders, during most in- person visits, at 
least some aspects of physical examination would be conducted 
(including blinded weight, blood pressure, heart rate, tempera-
ture and examination of the throat, heart, lungs and extremi-
ties).81 Laboratory tests, ECGs or radiological imaging are also 
commonly obtained in athletes with eating disorders during non- 
pandemic times.81 The provider must now consider if it is worth 
the risk of having athletes with eating disorders keep in- person 
appointments for these check- ups during the pandemic. If 
patients are malnourished or experience rapid weight loss, have 
frequent eating disorder behaviours, develop secondary amen-
orrhoea or experience syncope, near syncope or palpitations, 
then in- person examination and testing would be particularly 
prudent.81
For athletes with eating disorders but none of the above char-
acteristics, standard treatment approaches may be reconsid-
ered,80 with in- person evaluation cautiously delayed depending 
on an individual’s risk profile. Weighing risks versus benefits 
in discussions with the athlete and, as relevant, other members 
of the treatment team, is appropriate.18 One option is to have 
the athlete purchase a home blood pressure/pulse monitor, or 
to have institutions/leagues purchase those monitors for their 
athletes.18 Athletes can then monitor their vital signs on their 
own, possibly with the provider watching via telehealth.18 
However, it may be more problematic to ask athletes with eating 
disorders to monitor their own weights, which could trigger 
symptom worsening.18
Athletes who take stimulants also should also have regular 
monitoring of vital signs.
LEVELS OF CARE
As during non- pandemic times, some athletes will need higher 
levels of mental healthcare compared with standard outpatient 
treatment. These levels of care include: intensive outpatient 
(typically a few days a week for a few hours each day); partial 
hospitalisation (typically at least 5 days a week for at least 4 
hours per day); residential (residing in a facility reminiscent 
of a home for the length of treatment, which is often several 
weeks or more) and inpatient hospitalisation (in a traditional 
psychiatric unit, which may be freestanding or part of a multi-
specialty hospital). In some countries, mental health ‘hospital in 
the home’ initiatives have been expanded during COVID-19, 
to provide daily acute mental healthcare by specialist outreach 
teams.82 For some athletes, being on hiatus might seem like a 
good time for these types of treatments, for example, for severe 
ongoing eating disorders, depression, substance use disor-
ders, obsessive- compulsive disorder, trauma disorders or other 
mental health disorders. However, such programmes may have 
a higher threshold for admissions during the pandemic, espe-
cially if in- person participation is required.83 Moreover, some 
pandemic- related aspects of higher levels of care have changed, 
for example, in- person group therapies and family meetings are 
now less likely; providers will be wearing personal protective 
equipment; and visitors, including teammates who might other-
wise normally rally around a hospitalised member, are typically 
not allowed.83 84 On the other hand, some intensive outpatient 
and partial hospitalisation programmes have new virtual options 
for participation.85 However, while brief virtual programmes 
for some mental health disorders have demonstrated clinical 
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efficacy, their efficacy in half- day and full- day programmes 
remains unclear.80 Furthermore, some virtual programmes may 
not allow out- of- state/country participants, thereby limiting 
options for elite athletes.
Athletes with substance use disorders represent a special popu-
lation for whom careful consideration of higher levels of care 
is needed. Currently, admitting athletes with severe substance 
use disorders into the higher- level care they need may be chal-
lenging, but should be considered, since postponement could 
have negative consequences.86
Across diagnostic categories, providers should continue to seek 
higher levels of care for their athletes when risks of continuing 
outpatient management are too great. For example, athletes who 
are suicidal with plan and intent to act, manic, acutely psychotic 
or grossly negligent in self- care because of mental health symp-
toms should undergo inpatient hospitalisation.
RELEVANT PRINCIPLES OF MENTAL HEALTH INTERVIEWING 
AND DIAGNOSIS OF ATHLETES
An effective plan to manage mental health symptoms and disor-
ders cannot be developed unless a comprehensive biopsycho-
social diagnostic evaluation is undertaken. Here, we review 
salient points regarding mental health symptoms and disorders 
in athletes that are relevant to this pandemic.
The pandemic certainly could cause or worsen some mental 
health symptoms and disorders such as anxiety (eg, about 
contracting the virus), obsessive- compulsive disorder (eg, with 
increased obsessive hand washing), PTSD, depression and suicid-
ality in athletes,2 who are often young and thus developmentally 
less prepared to deal with the uncertainty that the pandemic 
has wrought. Athletes are used to being highly physically active, 
but with the sudden cessation of most sports and the movement 
of much academic instruction online, some athletes have had a 
sudden and marked reduction in physical activity.87 As physical 
activity is regarded as having antidepressant88 and anxiolytic89 
effects, this change alone could substantially worsen mental 
health. Other relevant factors in worsening mental health symp-
toms and disorders in athletes include: social isolation; cancelled 
schedules and games and associated uncertainty about how to 
recalibrate training plans; loss of income; loss of training venues 
and access to training staff, teammates and coaches; family 
infection risks; loss of daily routines and self- care; anxiety about 
contracting COVID-19 during sporting events or otherwise and 
persistent community distress and family conflicts, including 
living situations that might be high risk for interpersonal 
violence.3–5 87 90–92
It is also known that times of transition within sport repre-
sent particular challenges for elite athlete mental health.1 Cessa-
tion of sport due to the pandemic, with this equating to sport 
retirement for some athletes (eg, those who had been planning 
to retire after 2020, or those who had been in their last season 
of collegiate participation), could be particularly challenging 
transitions. Retirement from sport is associated with wors-
ening mental health if it is involuntary, there was less retirement 
planning, there is less social support and there is higher athlete 
identity.93 94 Retirement from sport due to COVID-19 is likely 
associated with many of those poor prognostic factors.
Finally, there are likely to be new stressors for athletes who 
return to sport once that is possible. For example, injuries might 
be more likely if resumption of prepandemic training levels is 
rapid, and return- to- play protocols for athletes who previously 
contracted COVID-19 may include cardiovascular assessment, 
which anecdotally incites anxiety for some athletes.6 Additionally, 
tactile communication (eg, touching via high fives or pats on 
the back) has historically been important among teammates as 
it promotes cooperation and trust during sporting events,95 but 
athletes may be required to avoid this form of communication 
in the near term.
Given these contextual stressors, providers may make new 
mental health diagnoses in athletes during this time,4 96 while 
taking care not to overpathologise normative and expected 
levels of adjustment stress that do not cause significant distress 
nor dysfunction. Much can presumably be done via virtual 
appointments as necessary. However, some diagnoses are more 
challenging to make without in- person assessment, such as a new 
diagnosis of ADHD. According to the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5), several symptoms to 
substantiate such a diagnosis must have been present prior to the 
age of 12 years,97 but the athlete might not be coming to clinical 
attention until now. The NCAA, WADA and some professional 
sports leagues prohibit use of stimulants unless various diagnostic 
criteria are met.98 99 The NCAA notes that those criteria for 
use of stimulants include consideration of use of ADHD rating 
scales.98 WADA specifies that ‘in the diagnostic assessment there 
should ideally be reference to the use of validated diagnostic 
instruments and scales assessing symptoms and impairment’.99 
Such testing, which can be lengthy and multimodal, may be chal-
lenging to carry out virtually. Any change in timelines needed to 
assess for this disorder should be communicated to athletes, and 
virtual options explored if possible.
Screening for suicidality and, if necessary, associated crisis 
planning, is important during this pandemic100 and informs 
management of an athlete’s care, especially for the level of care 
recommended. Definitive data are not yet available, but some 
are concerned that the pandemic could increase suicide risk.100 
Several factors that might contribute to such a risk, and about 
which providers should ask, include social isolation, economic 
difficulties and barriers to accessing usual mental health treat-
ment during the pandemic.100 Providers who are concerned 
about their athletes’ safety in the context of mental health 
should ask about access to firearms, especially given the recent 
surge in firearms sales in some countries.101 Even if guns are not 
purchased with the intent to end one’s life, their presence in the 
home is associated with higher risk of suicide.102 103 Reducing 
access to other means of suicide (eg, excessive medication, access 
to high buildings) is also indicated when conducting suicide risk 
assessment. Finally, suicides tend to peak in the late spring in 
the Northern Hemisphere, which overlaps with some peaks of 
COVID-19 impact,104 including its effect on spring and summer 
sports.
DISCUSSION
COVID-19 has wrought changes to most aspects of athletes’ 
lives, including their very identities and livelihoods. For some, 
the pandemic and attendant social isolation has presented an 
opportunity to develop or enhance their non- athlete identities, 
which may be beneficial to their mental health, particularly post-
retirement.94 Any such ‘benefits’, however, are far outweighed by 
the challenges presented by COVID-19. As it is unclear how long 
COVID-19- related changes will persist, providers must tailor 
assessment and treatment offerings accordingly. Athletes may be 
at heightened risk for mental health symptoms and disorders, 
and careful consideration of the pandemic’s impact on manage-
ment of those symptoms and disorders is paramount. General 
principles of high- quality healthcare should still be followed, 
with some flexibility. Mainstays of mental health management, 
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that is, psychotherapy and pharmacotherapy, remain. However, 
their implementation may be different during the pandemic. 
Extrapolation from prior pandemics is of little utility, but there 
is some ability to extrapolate what we know about use of virtual 
treatment modalities. Moreover, management and diagnostic 
considerations particular to athletes can be applied to what 
we know about the pandemic, to surmise impacts on athletes’ 
mental health and make appropriate recommendations. For 
example, athletes are more likely to have eating disorders than 
the general population, and certain aspects of the pandemic intu-
itively and anecdotally heighten that risk. Such disorders are of 
particular concern during the pandemic because many aspects of 
management would ideally occur in- person.
The research and associated recommendations included in 
this paper primarily represent and are suited for high- income 
countries; these have more health services compared with low- 
income and middle- income countries. There may be culturally 
appropriate ways to manage athlete mental health during this 
pandemic that do not fall under the usual published research and 
clinical categories of ‘psychotherapy’ and ‘pharmacotherapy’.
The current pandemic is an important opportunity for 
research on new methods of providing mental healthcare for 
athletes, and consideration should be given to whether these 
new methods should extend beyond the pandemic. For example, 
since elite athletes typically travel frequently, they might particu-
larly benefit from all types of telehealth even after the pandemic 
ends. However, they would still need access to the resources 
necessary to participate in telehealth, and providers would need 
to be mindful of any new disparities or untoward consequences 
that might result from increased use of telehealth. Security 
and confidentiality when undertaking telemental health with 
elite athletes should be serious considerations, given that this 
is a population who may be well known in the public sphere. 
Moreover, licensure regulations and insurance/payer coverage 
would need to change permanently for many athletes to partic-
ipate in telehealth services in the future. Furthermore, advocacy 
(ranging from individual providers to professional medical soci-
eties and government leaders) would be necessary to address 
health equity issues such as those related to digital technology 
and current insurance/payer coverage. In- person healthcare for 
mental health symptoms and disorders must remain an option, 
and future guidance should help providers of mental healthcare 
for athletes understand how best to blend virtual and in- person 
care. Finally, providers would need to be willing to provide 
care virtually on an ongoing basis. Historically, there has been 
limited uptake of telehealth services, attributed in large part to 
providers’ unwillingness to adopt this modality.105 The essen-
tially forced usage of virtual healthcare brought about by this 
pandemic might increase providers’ interest in using such tech-
nology in the long- term. Regardless of the modalities of care 
provided during the post- pandemic period, continued close 
screening for and management of mental health symptoms and 
disorders in elite athletes will be needed well into the future, as 
the impact on this population is likely to continue, even after 
return to sport.
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